steady-state in patients [Design Issues]

posted by qualityassurance – 2025-01-09 11:59 (516 d 23:43 ago) – Posting: # 24334
Views: 5,851

Hi Helmut,

Recently a paper1 is published which shows Novonordisk conducted steady state study to prove BE between different strengths (3 mg, 7 mg , 14 mg vs 1.5 mg, 4 mg, 9 mg) of semaglutide tablets and EMA accepted it. As a generic company can we use the same approach for EMA?

Regards,
QA

1 https://link.springer.com/article/10.1007/s13300-024-01674-8

Complete thread:

UA Flag
Activity
 Admin contact
23,653 posts in 4,991 threads, 1,570 registered users;
216 visitors (0 registered, 216 guests [including 17 identified bots]).
Forum time: 12:43 CEST (Europe/Vienna)

In theory, there is no difference between theory and practice.
But, in practice, there is.    Jan L.A. van de Snepscheut

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5